Flush Thrush: Bluebird's IPO At 'Beak' Value, Gets $101M
By Randy Osborne
Thursday, June 20, 2013
Bluebird Bio Inc.'s above-the-range initial public offering (IPO) sold about 5.9 million shares at $17 each to raise $101 million for a gene therapy strategy that deploys stem cells harvested from the patient's bone marrow, and the lead program is slated to kick off a Phase II/III trial late this year in childhood cerebral adrenoleukodystrophy (CCALD), caused by the buildup of fatty acids that damages the myelin sheath.
Outside of the US
Part of Thomson Reuters
Note: our contact information has changed
In the U.S. and Canada: +1-800-336-4474
Outside the U.S.: +44-203-684-1796
Hours: Monday - Friday, 8:00am - 6:00 pm EST
© 2017 Thomson Reuters. Reproduction, reposting content is strictly prohibited.